Repositive is accelerating the development of precision cancer therapies by working with biopharmas and Contract Research Organisations (CROs) to improve the predictivity of their research. Its Cancer Models Scout service, enables biopharmas to identify the most suitable models from its world-leading inventory of over 4,500 models from CRO partners across the globe who have first-class expertise and years of experience running such studies.